Developing a new treatment for chronic itching in skin diseases
Official title: IND Enabling Studies for the Development of Pruritus Therapeutic PRA-523
Funded at Praeventix, LLC · NIH-10911296 · Data updated 2026-11-12
This study is looking for a new way to help people with Atopic Dermatitis who suffer from chronic itching by testing a new drug called PRA-523 that targets certain receptors in the body, and if you join, you could help improve treatments for this frustrating condition!
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Praeventix, LLC NIH-funded |
| Lab location | 1 site (Exton, United States) |
| Project start | July 1, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $728,119 |
| NIH project number | 5R44AR081768-03 |
| Project ID | NIH-10911296 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who experience chronic itching associated with Atopic Dermatitis.
✕Less likely to help
Patients with acute pruritus or those who do not have Atopic Dermatitis may not benefit from this research.
What this research studies
This research focuses on finding a new therapeutic approach to alleviate chronic pruritus, particularly in patients with Atopic Dermatitis (AD). It aims to explore the role of serotonin receptors in the sensation of itch and how they can be targeted to provide relief. The study will investigate the effectiveness of a new drug, PRA-523, in reducing itch symptoms by targeting specific pathways involved in the itch response. Patients participating in this research may help advance treatment options for chronic itch, which significantly impacts quality of life.
Why it matters
Potential benefit: If successful, this research could lead to a new effective treatment for chronic itching, improving the quality of life for patients suffering from skin diseases like Atopic Dermatitis.
How similar studies have gone: Previous research has shown promise in targeting serotonin pathways for itch relief, indicating potential success for this novel approach.
Where this research is happening
-
Praeventix, LLC
Exton, United States Active
Researchers
- Principal investigator: Pippin, Douglas Anthony — Praeventix, LLC
- Study coordinator: Pippin, Douglas Anthony
Related research
Other NIH-funded projects on the same topics.
-
Understanding 5-HT7 Modulators to Help People with Opioid Use Disorder
A short study to see if targeting a serotonin receptor (5-HT7) can help reduce opioid craving and reliance in people with opioid use disorder.
-
Investigating how serotonin receptors affect cocaine addiction in rats
This study is looking at how a specific serotonin receptor in the brain might affect cocaine addiction, using rats to help find new ways to treat people struggling with this issue.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.